์ฝ˜ํ…์ธ ๋กœ ๊ฑด๋„ˆ๋›ฐ๊ธฐ
Merck
๋ชจ๋“  ์‚ฌ์ง„(3)

Key Documents

์ถ”๊ฐ€ ์ž๋ฃŒ

G5627

Sigma-Aldrich

Guaiacol glyceryl ether

≥98% (GC)

๋™์˜์–ด(๋“ค):

3-(o-Methoxyphenoxy)-1,2-propanediol, Glycerol guaiacolate, Guaifenesin

๋กœ๊ทธ์ธ์กฐ์ง ๋ฐ ๊ณ„์•ฝ ๊ฐ€๊ฒฉ ๋ณด๊ธฐ
๋ชจ๋“  ์‚ฌ์ง„(3)

About This Item

์‹คํ—˜์‹(Hill ํ‘œ๊ธฐ๋ฒ•):
C10H14O4
CAS Number:
93-14-1
Molecular Weight:
198.22
EC Number:
202-222-5
MDL number:
MFCD00016873
UNSPSC ์ฝ”๋“œ:
12352100
PubChem Substance ID:
57654212
NACRES:
NA.22

Quality Level

200

๋ถ„์„

≥98% (GC)

SMILES string

COc1ccccc1OCC(O)CO

InChI

1S/C10H14O4/c1-13-9-4-2-3-5-10(9)14-7-8(12)6-11/h2-5,8,11-12H,6-7H2,1H3

InChI key

HSRJKNPTNIJEKV-UHFFFAOYSA-N

์œ ์‚ฌํ•œ ์ œํ’ˆ์„ ์ฐพ์œผ์‹ญ๋‹ˆ๊นŒ? ๋ฐฉ๋ฌธ ์ œํ’ˆ ๋น„๊ต ์•ˆ๋‚ด

๊ด€๋ จ ์นดํ…Œ๊ณ ๋ฆฌ

ํ”ฝํ† ๊ทธ๋žจ

Exclamation mark
GHS07

์‹ ํ˜ธ์–ด

Warning

์œ ํ•ด ๋ฐ ์œ„ํ—˜ ์„ฑ๋ช…์„œ

H302

์˜ˆ๋ฐฉ์กฐ์น˜ ์„ฑ๋ช…์„œ

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point (ยฐF)

Not applicable

Flash Point (ยฐC)

Not applicable

๊ฐœ์ธ ๋ณดํ˜ธ ์žฅ๋น„

dust mask type N95 (US), Eyeshields, Gloves

์‹œํ—˜ ์„ฑ์ ์„œ(COA)

์ œํ’ˆ์˜ ๋กœํŠธ/๋ฐฐ์น˜ ๋ฒˆํ˜ธ๋ฅผ ์ž…๋ ฅํ•˜์—ฌ ์‹œํ—˜ ์„ฑ์ ์„œ(COA)์„ ๊ฒ€์ƒ‰ํ•˜์‹ญ์‹œ์˜ค. ๋กœํŠธ ๋ฐ ๋ฐฐ์น˜ ๋ฒˆํ˜ธ๋Š” ์ œํ’ˆ ๋ผ๋ฒจ์— ์žˆ๋Š” โ€˜๋กœํŠธโ€™ ๋˜๋Š” โ€˜๋ฐฐ์น˜โ€™๋ผ๋Š” ์šฉ์–ด ๋’ค์—์„œ ์ฐพ์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

์ด ์ œํ’ˆ์„ ์ด๋ฏธ ๊ฐ€์ง€๊ณ  ๊ณ„์‹ญ๋‹ˆ๊นŒ?

๋ฌธ์„œ ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ์—์„œ ์ตœ๊ทผ์— ๊ตฌ๋งคํ•œ ์ œํ’ˆ์— ๋Œ€ํ•œ ๋ฌธ์„œ๋ฅผ ์ฐพ์•„๋ณด์„ธ์š”.

๋ฌธ์„œ ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ ๋ฐฉ๋ฌธ

์ด๋ฏธ ์—ด๋žŒํ•œ ๊ณ ๊ฐ

Slide 1 of 4

1 of 4

Guaiacol solution certified reference material, 2000 μg/mL in methanol, ampule of 1 mL

CRM40484

Guaiacol solution

2-Bromo-2′-acetonaphthone 99%

Sigma-Aldrich

105120

2-Bromo-2โ€ฒ-acetonaphthone

(ยฑ)-Chlorpheniramine maleate salt ≥99% (perchloric acid titration)

Sigma-Aldrich

C3025

(ยฑ)-Chlorpheniramine maleate salt

Guaiacol Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1136

Guaiacol

Mehdi Hatami et al.
Journal of separation science, 34(21), 2933-2939 (2011-10-06)
A simple, rapid, and efficient method, dispersive liquid-liquid microextraction (DLLME) coupled with high-performance liquid chromatography-fluorescence detector, has been developed for the determination of guaifenesin (GUA) enantiomers in human urine samples after an oral dose administration of its syrup formulation. Urine
Siavash Riahi et al.
Drug testing and analysis, 3(5), 319-324 (2011-05-21)
The accuracy in predicting different chemometric methods was compared when applied on ordinary UV spectra and first order derivative spectra. Principal component regression (PCR) and partial least squares with one dependent variable (PLS1) and two dependent variables (PLS2) were applied
Sara Nannarone et al.
American journal of veterinary research, 73(7), 959-967 (2012-06-29)
To compare the ability of 2 partial IV anesthesia (PIVA) techniques to maintain anesthesia, compared with isoflurane alone, in horses. 45 horses. Client-owned horses requiring general anesthesia for a variety of procedures of at least 1 hour's duration were randomly
Helmut Albrecht et al.
Respiratory research, 13, 118-118 (2012-12-29)
Guaifenesin is a component of medicines used to improve symptoms associated with upper respiratory tract infections. Patient-reported outcome instruments are valuable for evaluating symptom improvements; however, a validated tool to assess efficacy of mucoactive drugs does not exist. We compared
C H Yeong et al.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 69(9), 1181-1184 (2011-05-10)
Neutron activation of Sm-152 offers a method of radiolabeling for the in vivo study of oral dose formulations by gamma scintigraphy. Reproducibility measurements are needed to ensure the robustness of clinical studies. 204 enteric-coated guaifenesin core tablets (10mg of Sm(2)O(3))
๋ชจ๋“  ๊ด€๋ จ๋œ ์„œ๋ฅ˜ ๋ณด๊ธฐ

์ž์‚ฌ์˜ ๊ณผํ•™์žํŒ€์€ ์ƒ๋ช… ๊ณผํ•™, ์žฌ๋ฃŒ ๊ณผํ•™, ํ™”ํ•™ ํ•ฉ์„ฑ, ํฌ๋กœ๋งˆํ† ๊ทธ๋ž˜ํ”ผ, ๋ถ„์„ ๋ฐ ๊ธฐํƒ€ ๋งŽ์€ ์˜์—ญ์„ ํฌํ•จํ•œ ๋ชจ๋“  ๊ณผํ•™ ๋ถ„์•ผ์— ๊ฒฝํ—˜์ด ์žˆ์Šต๋‹ˆ๋‹ค..

๊ณ ๊ฐ์ง€์›ํŒ€์œผ๋กœ ์—ฐ๋ฝ๋ฐ”๋ž๋‹ˆ๋‹ค.